- Items which should not be routinely prescribed in primary care: A Consultation on guidance for CCGs -
Thyroid UK has now received a letter from NHS England regarding the above consultation. Please note the wording, "The proposed guidance would not remove the clinical discretion of the prescriber in deciding what is in accordance with their professional duties."
The impression I get is that they think that those getting T3 is making it unfair on those that aren't, so let's take it away so everyone is the same!
Please take part in the survey and spread this far and wide to all the media platforms you belong to, families, friends, colleagues, doctors etc. etc. We must stop them taking our liothyronine away from us!
21st July 2017
NHS Clinical Commissioners (NHSCC) and NHS England have developed a proposal to improve patient care by no longer routinely prescribing 18 medicines which are either:
•clinically ineffective; unsafe; or not cost effective; or
•where the NHS can offer a clinically-proven alternative for patients.
In partnership we brought together an expert clinical working group earlier this year to review the evidence, and they have developed recommendations for a public consultation.
The objective is to produce commissioning guidance to support clinical commissioning groups (CCGs) in their decision-making, to address unwarranted variation, and to provide clear national advice to make local prescribing practices more effective. Any savings from implementing the proposals will be reinvested in improving patient care.
The consultation is open from 21 July to 21 October 2017: engage.england.nhs.uk/consu...
While many doctors and other prescribers are no longer prescribing these 18 medicines for patients, the evidence shows that there is variation across the country and that the NHS currently spends £141 million p.a. on these medicines.
Clearly the NHS needs a fair and consistent national position for everyone. As part of its national commissioning role, NHS England is taking a lead on this initiative and is working with NHSCC on behalf of CCGs from across England.
Subject to the outcome of the consultation, guidance on the initial 18 medicines is likely to be published by NHS England and CCGs will be asked to consider its implementation in their communities, ensuring they take into account their legal duties to advance equality and to reduce health inequalities. The proposed guidance would not remove the clinical discretion of the prescriber in deciding what is in accordance with their professional duties.
NHS England and NHSCC are also seeking people’s views on whether a wider list of 3,200 products that are available over-the-counter, without prescription, may be considered appropriate for future restriction. At this stage, we are seeking views generally on this area, for further work and consideration by the clinical working group.
We would encourage everyone who is interested to respond to the consultation and would be grateful if you could share this letter through your networks.
Lauren Hughes Julie Wood
Director of Clinical Policy Chief Executive
NHS Clinical Commissioners